The Manufacturers Life Insurance Company Has $4.01 Million Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

The Manufacturers Life Insurance Company lessened its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 14.9% in the fourth quarter, Holdings Channel.com reports. The firm owned 122,094 shares of the biopharmaceutical company’s stock after selling 21,337 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Agios Pharmaceuticals were worth $4,012,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Venturi Wealth Management LLC bought a new position in Agios Pharmaceuticals in the 4th quarter valued at approximately $33,000. Wingate Wealth Advisors Inc. bought a new stake in Agios Pharmaceuticals in the fourth quarter valued at approximately $53,000. Sterling Capital Management LLC increased its position in Agios Pharmaceuticals by 818.0% during the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 1,587 shares during the period. KBC Group NV raised its holdings in Agios Pharmaceuticals by 30.5% during the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 611 shares during the last quarter. Finally, AlphaQuest LLC increased its position in shares of Agios Pharmaceuticals by 106.2% during the fourth quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 2,338 shares during the period.

Analysts Set New Price Targets

AGIO has been the topic of a number of recent analyst reports. HC Wainwright initiated coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a “buy” rating and a $58.00 price objective on the stock. Scotiabank decreased their price target on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a “sector outperform” rating for the company in a research note on Friday, May 2nd. Finally, StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, May 1st. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $56.00.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the business’s stock in a transaction that occurred on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the transaction, the director now directly owns 149,220 shares of the company’s stock, valued at approximately $3,864,798. The trade was a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.93% of the stock is currently owned by corporate insiders.

Agios Pharmaceuticals Stock Performance

Shares of AGIO stock opened at $28.07 on Friday. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58. The company has a market capitalization of $1.63 billion, a P/E ratio of 2.48 and a beta of 0.77. The stock has a 50 day moving average price of $29.35 and a two-hundred day moving average price of $37.40.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.80) by $0.25. The business had revenue of $8.73 million for the quarter, compared to analyst estimates of $9.86 million. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. As a group, equities analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.